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Whole exome sequencing combined with linkage
analysis identifies a novel 3bp deletion in NR5A1
Stefanie Eggers1,2, Katherine R Smith3,4, Melanie Bahlo3,5, Leendert HJ Looijenga6, Stenvert LS Drop7,
Zulfa A Juniarto8, Vincent R Harley9, Peter Koopman10, Sultana MH Faradz8 and Andrew H Sinclair*,1,2
Disorders of sex development (DSDs) encompass a broad spectrum of conditions affecting the development of the gonads and
genitalia. The underlying causes for DSDs include gain or loss of function variants in genes responsible for gonad development
or steroidogenesis. Most patients with DSD have an unknown genetic etiology and cannot be given an accurate diagnosis.
We used whole exome capture and massively parallel sequencing to analyse a large family with 46,XY DSD and 46,XX premature
ovarian insufficiency. In addition, we used a recently developed method for linkage analysis using genotypes extracted from the
MPS data. This approach identified a unique linkage peak on chromosome 9 and a novel, 3 bp, in-frame deletion in exon six of
NR5A1 (steroidogenic factor-1 or SF1) in all affected individuals. We confirmed that the variant disrupts the SF1 protein and its
ability to bind and regulate downstream genes. NR5A1 has key roles at multiple points in gonad development and steroidogenic
pathways. The variant described here affects the function of SF1 in early testis development and later ovarian function, ultimately
leading to the 46,XY DSD and 46,XX premature ovarian insufficiency phenotypes, respectively. This study shows that even at low
coverage, whole exome sequencing, when combined with linkage analysis, can be a powerful tool to identify rapidly the disease-
causing variant in large pedigrees.
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INTRODUCTION
Disorders of sex development (DSDs) cover a wide spectrum of
phenotypes, ranging from complete sex reversal to ambiguous
genitalia, the latter affecting 1 in 4500 births.1
Patients with 46,XY partial or complete gonadal dysgenesis have
either underdeveloped testes, ovotestes (partial gonadal dysgenesis) or
streak gonads (complete gonadal dysgenesis). Disruption of testis
development leads to either undervirilization of the external genitalia,
ambiguous genitalia or a female external phenotype. The clinical
management of these complex conditions is made difficult because up
to 70% of 46,XY gonadal dysgenesis cases lack a diagnosis and the
underlying molecular cause remains unknown.2 However, point
variants, deletions or duplications of genes such as sex-determining
region Y (SRY), SRY-related HMG-box, gene 9 (SOX9), nuclear
receptor subfamily 5, group A, member 1 (NRA51), and mitogen-
activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
(MAP3K1) have been shown to be responsible for 30% of 46,XY DSD
cases.3
Premature ovarian insufficiency (POI) in 46,XX individuals is
characterized by early failure of ovarian function, affecting 1% of
women.4 In the majority of 46,XX POI cases, the underlying genetic
cause remains unknown. Few genes such as autoimmune regulator
(AIRE; causing autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED) syndrome) and forkhead box L2 (FOXL2) have
been associated with 46,XX POI in a minority of patients.5
Studies in mouse have identified Nr5a1 as a key gene involved in
gonadal sex determination, differentiation, and maintenance.3 Nr5a1
encodes steroidogenic factor 1 (SF1), an orphan nuclear receptor
expressed early in the bipotential gonad, and later in the developing
and mature testis and ovary. Nr5a1-null XY mice show streak gonads
and feminization, which mimics the phenotype of patients affected by
46,XY complete gonadal dysgenesis. Genes downstream of NR5A1 in
the testis and ovary have been identified by analysing different mouse
strains and human fetal gonads. These include genes required for
testis and ovary development, such as SOX9, anti-Mu¨llerian hormone
(AMH), and nuclear receptor subfamily 0, group b, member 1 (Nr0b1
or Dax1), as well as, in particular, gonadal steroidogenesis.6–8
Variants in and around NR5A1 are causative for 46,XY gonadal
dysgenesis.9,10 A recent study analysed four families with individuals
exhibiting 46,XY gonadal dysgenesis and female relatives affected by
46,XX POI.11 NR5A1 was found to be the causative gene for both
phenotypes in all four families, representing the first link of NR5A1 to
46,XX POI. The authors also found variants in NR5A1 in two
sporadic 46,XX POI cases. Another study identified 10 novel variants
in NR5A1 in a cohort of sporadic cases of 46,XY gonadal dysgenesis
and 46,XX POI.12 Here we describe the analysis of a multigeneration
family affected by 46,XY DSD and 46,XX POI, using low-coverage
whole exome sequencing combined with linkage analysis. This approach
was extremely powerful in quickly refining the search area within the
exome down to the nucleotide level, allowing rapid identification of a
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novel 3-bp deletion in NR5A1 as the causative variant in this family.
In addition, we analysed the function of the mutant SF1 protein to
investigate the biologic consequences of the lesion.
MATERIALS AND METHODS
Clinical data: family members with 46,XY DSD
Case II:8: The 46,XY DSD patient II:8 (later referred to as ‘unclassified 46,XY
DSD’) presented with ambiguous genitalia and gynaecomastia, severe peno-
scrotal hypospadias, bifid scrotum, micropenis, small bilateral testis (2–3ml),
and primary infertility. Owing to the mainly male external genitalia, he was
raised as a male.
Case III:1: This 46,XY gonadal dysgeneis patient presented with atrophy of
testis (bilateral small inguinal palpable testis;o1ml), with labia major (fusion
of labia major, which resembles a scrotum and is darker in colour) and small
labia minor, blind ending vagina, and an enlarged clitoris. The child was raised
as a girl. Abdominal testes were removed and the patient will have lifelong
hormonal treatment. Pathology results from the removed testis revealed low
number of Leydig cells and atrophy of seminiferous tubules. No malignant cells
and spermatozoa, but few spermatid cells were detected. Low testosterone
levels (8ng/dl before and o20ng/dl after gonadectomy) were measured.
Case III:2: Presented with 46,XY gonadal dysgenesis, micropenis (phallus
length 5.4 cm at the age of 10 years), Quigley stage 2, Tanner stage V, severe
scrotal hypospadias (meatus at glans), bifid scrotum, severe chordee, and small
bilateral testis (both in scrotum and both 5ml volume). The patient underwent
plastic surgery three times to repair the hypospadias and was raised as a male.
No uterus or ovary could be detected.
Clinical data: family members with 46,XX POI
The four female relatives who presented with 46,XX POI (I:2, II:2, II:4, and
II:7) were all diagnosed at different ages (II:4 onset at 35, and II:7 at 24 years of
age; for I:2 and II:2 the age of onset is unknown), by onset of secondary
amenorrhoea.
Patient DNA samples
DNA from the 15 family members was extracted from peripheral EDTA blood
samples according to a standard protocol (desalting method). Approval for this
study was obtained by the Human Ethics Committee of the Faculty of
Medicine, Diponegoro University, Semarang, Indonesia. All patients and
family members gave their informed consent before taking part in this study.
This study also received approval from the Human Ethics Committee at the
Royal Children’s Hospital, Melbourne, Victoria, Australia.
Exome capture, sequencing, and bioinformatic analysis
Exome capture (TruSeq Exome Enrichment Kit; Illumina Inc., San Diego, CA,
USA) and sequencing (Illumina HiSeq 2000; Illumina) were performed by the
Australian Genome Research Facility (Melbourne, VIC, Australia). The 100 bp
paired-end reads were aligned to UCSC hg19 using Novoalign version 2.07.09
in paired-end mode (http://www.novocraft.com). Reads mapping to multiple
locations were discarded; presumed PCR duplicates were discarded using the
MarkDuplicates utility from Picard (http://picard.sourceforge.net/). Variants
were detected using the mpileup and bcftools view commands from SAMtools
version 0.1.17,13,14 specifying parameters C50 and q13. Low confidence
variants were discarded using the vcfutils.pl varFilter script from the same
program. Variants were annotated against the UCSC KnownGene annotation,
dbSNP132, and the May 2011 release of the 1000 Genomes Project15 using
ANNOVAR.16 In silico analysis of the functional effects of coding non-
synonymous variants was performed with SIFT17 and HumVar-trained
PolyPhen-2 v.2.1.0.18 We used SAMtools to infer, from the exome sequence
data, genotypes at the location of HapMap Phase II and III SNPs, specifying
parameters cg and t0.5.19 Parametric multipoint linkage analysis was
performed using MERLIN20 under a fully penetrant autosomal dominant
model with a 0% phenocopy rate and a disease allele frequency of 0.00001.
SNP allele frequencies were obtained from HapMap CEU (Utah residents with
ancestry from northern and western Europe from the CEPH collection)
genotypes.
In silico prediction on the wild-type and mutant protein
To predict changes between the wild-type and mutant protein structure, an in
silico prediction of the two protein structures was performed using the protein
comparative modelling server 3D-JIGSAW (http://bmm.cancerresearchuk.org/
B3djigsaw/).
Plasmids
The mammalian expression vector pCMV6-Entry-hNR5A1 (RC207577;
OriGene Technologies Inc., Rockville, MD, USA) containing the human cDNA
ORF of NR5A1 was used to obtain the expression vector containing the mutant
NR5A1 cDNA (pCMV6-Entry-hNR5A1-p.(Lys372del)). Site-directed mutagen-
esis was performed using the QuickChange II XL Site-directed Mutagenesis Kit
(Agilent Technologies Inc., Santa Clara, CA, USA) according to the manu-
facturer’s instructions (for primer sequences see Supplementary Table S5). To
create the pGL4.10-hNR0B1 construct for dual-luciferase reporter assays, the
human NR0B1 (hNR0B1) promoter was PCR amplified (for PCR primer
sequences see Supplementary Table S5) and cloned into the pGL4.10 vector
(Promega Corporation, Madison, WI, USA) using the XhoI and HindIII
restriction sites within the multiple cloning site.
Cell culture, transfections, and preparation of nuclear extracts
COS7 (monkey kidney cell line), KK-1 (mouse Granulosa cell line), 15P-1
(mouse Sertoli cell line), and Hek293 (human embryonic kidney) cells were
maintained in D-MEM supplemented with 10% FBS and 1.8 g/l NaHCO3 and
incubated at 37 1C. For nuclear extracts, cells were transfected with 30mg of
either the wild-type or mutant (pCMV6-Entry-hNR5A1 or pCMV6-Entry-
hNR5A1-p.(Lys372del)) construct. The transfection reagent Lipofectamine
2000 (Invitrogen, Thermo Fisher Scientific Inc., Waltham, MA, USA) was
used for transfections. Cells were harvested 48h posttransfection and nuclear
extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction
Reagents (Thermo Fisher Scientific Inc.). Protein concentrations were deter-
mined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc.).
Absorbance at 562 nm was measured using the Infinite M200 Pro plate reader
(Tecan, Ma¨nnedorf, Switzerland).
SDS-PAGE and western blot
Fifteen micrograms of nuclear extract was diluted to 30ml with H2O, 10ml of
4 loading buffer (50% (v/v) glycerol, 0.16 M Tris-HCl (pH 6.8), 2% (w/v)
SDS, 0.01% (w/v) bromophenol blue, and 350mM DTT) was added, and the
samples were denatured at 95 1C for 15min. Total protein of 7.5mg and 5ml of
Precision Plus Protein Dual Color Standard (Bio-Rad Laboratories, Hercules,
CA, USA) were loaded onto a NuPAGE 10% Bis-Tris gel. SDS-PAGE was
performed in 1 NuPAGE MOPS running buffer (Invitrogen) at 100V for
2 h. After electrophoresis, proteins were blotted onto a PVDF membrane (GE
Healthcare Bio-Sciences, Pittsburgh, PA, USA) using 1 NuPAGE Transfer
buffer (Invitrogen) with 20% methanol overnight at 4 1C at 100mA. Blocking
and incubation with primary (1:1000 dilutions) and secondary antibodies
(donkey anti-rabbit AlexaFlour 488 and donkey anti-goat AlexaFluor 488;
Invitrogen) was performed as described previously. Fluorescence signals were
visualized using a Typhoon Trio Variable Mode Imager (GE, Fairfield, CT, USA).
Electrophoretic-mobility shift assays
Fluorescently labelled oligonucleotide (0.5 nmol each) and the corresponding
unlabelled synthetic complementary strand, containing the mouse Nr0b1 SF1-
responsive element (other SF1-responsive elements were also tested – data not
shown; for oligosequences see Supplementary Table S5), were annealed and
diluted to 10ng/ml in 1 TE buffer. Fifteen micrograms of either the wild-
type or mutant SF1 overexpression nuclear extracts were incubated in 2.5
binding buffer21 for 10min at RT. One microgram of poly(dI–dC) (Roche
Diagnostics Pty Ltd, Rotkreuz, Switzerland), 5ml of a rabbit anti-FLAG
antibody (for supershifts) (Sigma-Aldrich, Castle Hill, NSW, Australia), and
water were added to a final volume of 48ml and incubated for 30min. Two
microliters (20 ng) of double-stranded probes were added to a final volume of
50ml. The samples were incubated for 30min and the reaction stopped by
adding 5ml of 6 loading buffer (250mM Tris-HCl, 40% (v/v) glycerol, and
0.01% (w/v) Orange G). Twenty microliters of each reaction was loaded onto a
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7.5% Mini-Protean TGX gel (Bio-Rad) and DNA–protein complexes were
separated by electrophoresis at 100V for 90min. Fluorescence signals were
visualized using a Typhoon Trio Variable Mode Imager (GE).
Dual-luciferase reporter assays
Cells were split onto 96-well plates (Nunc) 12–24h before transfection and
transfected with 75 ng of the reporter construct, pGL4.10-hNR0B1, and 15ng
of the Renilla construct (pRL-TK) for normalization of transfection efficiency.
For the transactivation assay, cells were also co-transfected with 50 ng of either
wild-type or mutant pCMV6-Entry-hNR5A1 construct. To adjust for differ-
ences in the amount of DNA added to each reaction, an independent, non-
active plasmid (pSLAX) was used to adjust total DNA amounts to 240 ng for
each reaction. Lipofectamine 2000 (Invitrogen) was used as a transfection
reagent. Cells were harvested 48h posttransfection and luciferase activity was
measured using the Dual-Luciferase Reporter 1000 Assay System Kit
(Promega) according to the manufacturer’s instructions. Chemiluminescence
was measured on an Infinite M200 Pro plate reader (Tecan). Each experiment
was performed in biologic triplicate.
RESULTS
Large families are rare in DSD research, because most DSDs result in
infertility. As large pedigrees are an extremely powerful tool for
genetic linkage analysis, we decided to sequence the entire exome of
Figure 1 A novel 3-bp deletion in exon 6 of NR5A1 (exons are numbered as in NG_008176.1) was identified in a multigeneration Indonesian family to be
associated with 46,XY DSD and 46,XX POI. (a) Pedigree of the family, showing all 15 individuals who were available for this study. Squares and circles
represent males and females, respectively. Open symbols indicate unaffected individuals, and filled squares and circles highlight affected individuals.The
46,XY gonadal dysgenesis (46,XY GD) patients were assigned male or female symbols according to their phenotype and assigned gender. The 46,XX POI
patients are labelled with 46,XX POI below the symbol. The pedigree has been reduced to the individuals who were available for the study for simplicity and
for the sake of confidentiality. (b) Schematic view of the NR5A1 genomic region on chr9:g.127243515–127 269 699 (GRCh37/hg19) including the exon–
intron structure (NR5A1 is located on the reverse strand, but shown here in its 50–30 orientation from left to right). Exon 6 is highlighted in red. (c) Sanger
sequencing of an unaffected and affected individual, showing the wild-type exon 6 sequence (unaffected) and the heterozygous, 3-bp deletion
(c.1114_1116del) in one affected individual.
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all 15 individuals from a multigeneration family from Indonesia
(Figure 1a).
Exome capture, sequencing, and bioinformatic analysis
Picard MarkDuplicates software estimated rates of PCR duplication to
be very high, ranging from 83.3 to 96.7% of uniquely aligned reads
(Supplementary Table S1). As a result, coverage of targeted bases
following duplicate removal was very low (Supplementary Table S2),
with median coverage ranging between 2 and 9 (median 3).
We attempted to infer genotypes at the locations of 4 071 900
HapMap Phase II and III SNPs. Genotypes were set to missing, unless
an SNP was covered by Z5 reads with base and mapping qualities
Z13. We discarded SNPs where genotypes were missing for more
than 10 of the 15 exomes, resulting in 57 666 SNPs being retained. We
then discarded 414 SNPs where genotypes were inconsistent with
Mendelian inheritance and 37 685 SNPs where non-missing genotypes
did not vary between individuals. Finally, we chose a subset of 4814
SNPs in approximate linkage equilibrium for linkage analysis;22 on
average, CEU individuals are heterozygous for 38% of these markers.
Individual genotyping rates for these SNPs ranged between 0.8 and
96.7% (median 21.5%) (Supplementary Table S3).
Linkage analysis identified two peaks on chromosomes 9 and 18
achieving maximum LOD scores of 2.69 and 2.42 (Figure 2). Positive
LOD scores were obtained between 128.4 and 159.6 cM (rs1930713–
rs4842247) on chromosome 9 and between 29.1 and 48.0 cM
(rs767300–rs17448282) on chromosome 18. Given the high number
of genotypes missing, we examined the robustness of our results by
using MERLIN’s – sample option to sample 10 sets of haplotypes
according to their likelihood (eg Supplementary Figure S1). This
allows assessment of the uncertainty of the haplotype inference; the
less an individual’s inferred haplotypes vary across samples, the more
confidence we have in the haplotyping. For the chromosome 9 peak,
all 10 sets of haplotypes were consistent with the autosomal dominant
model for 14 of the family members (eg Supplementary Figure S1),
indicating high confidence in the results. Inference could not be
performed for the remaining individual, affected II:7, for whom all
genotypes within the linkage region were missing. For the chromo-
some 18 peak, only two haplotype sets accorded with the genetic
model for 14 family members, indicating that we cannot be very
confident of linkage. Unaffected II-3 was missing all genotypes within
the linkage region.
Of the 300 591 variants detected in at least one of the 15 exomes,
4453 variants were located within one of the two linkage peaks; 1148
of these were rare (not present or present at a frequencyr0.01 in the
1000 Genomes Project). Of these, 45 variants were predicted to affect
protein sequence and/or splicing. Given the low coverage, we did not
apply a strict genotype filter; instead, we retained variants that were
not detected in the eight unaffected exomes, but were detected in at
least two affected exomes. This reduced the list of candidate variants
to five (Supplementary Table S4). One of these variants, a 3-bp
deletion removing a single amino acid, is located within exon 6 of
NR5A1 (NM_004959.4:c.1114_1116del [p.(Lys372del)]; data have
been submitted to the NR5A1 gene variant database at http://
www.LOVD.nl/NR5A1, patient ID 0063642.) (see Figure 1b).
Supplementary Figure S2 shows read alignments at the location of
the NR5A1 variant for affected and unaffected family members with
coverage at this location. Sanger sequencing indicated that all seven
affected family members were heterozygous for the deletion, whereas
the six unaffected family members were all wild type, as were the two
girls considered at risk of developing 46,XX POI (III:3 and III:4; see
Figure 1b and c).
In silico prediction on the wild-type and mutant SF1 protein
The heterozygous, 3-bp in-frame c.1114_1116del in exon 6 of NR5A1
results in deletion of the lysine at position 372 (p.(Lys372del)) of SF1,
within the predicted ligand-binding domain (LBD; see Figure 3a).
Although recent publications have described phosphatidylinositols,
sphingosine, and phospholipids as potential ligands for SF1, their
biologic role remains to be elucidated.23–25 To investigate the potential
biologic relevance of the p.(Lys372del) variant, we performed an in
silico prediction on the wild-type and mutant proteins using the
online protein comparative modelling server 3D-JIGSAW (http://
bmm.cancerresearchuk.org/B3djigsaw/). Direct comparison of the
two predicted protein structures (Figure 3a–c) revealed truncation
of helix 8 of the LBD at position 372 in the mutant protein.
Furthermore, the loss of the b-pleated sheets in the LBD and
the DNA-binding domain (DBD) indicated a potential loss of the
DNA-binding ability of the mutant protein compared with the wild-
type protein. Also, the tertiary structure of the whole protein was
predicted to change slightly, indicating a crucial role of Lys372 in the
wild-type SF1 protein structure.
Functional assays of SF1 activity
We assessed whether the mutant SF1 protein was correctly trans-
located into the nucleus. Using immunofluorescence, we confirmed
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Figure 2 Genome-wide parametric LOD scores under a fully penetrant autosomal dominant inheritance model for the Indonesian family.
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that import of the mutant SF1 protein into the nucleus was not
affected by the p.(Lys372del) variant (data not shown).
To investigate the potential effect of the p.(Lys372del) variant on
the DNA-binding ability of SF1, as predicted by 3D-JIGSAW, we
performed electrophoretic mobility shift assays (EMSAs) and dual-
luciferase reporter assays using known SF1-responsive elements.
Figure 4b shows the results for the wild-type and mutant SF1
proteins, using the mNr0b1 (mDax1) SF1-responsive element.21
Western blot analysis was used to ensure similar levels of wild-type
and mutant SF1 protein, nuclear extracts were loaded (see Figure 4a).
The binding of wild-type SF1 to the mNr0b1 SF1-responsive element
yielded two signals as the probe contains two overlapping SF1-
binding sites, one on each of the DNA strands. The lower band
represents one molecule of SF1 and the second higher band represents
two SF1 molecules bound to the probe (see Figure 4b). To confirm
that both signals were caused by SF1 binding, we performed
supershifts, using an anti-FLAG antibody, which recognizes
both the wild-type and mutant SF1 proteins (expressed via the
Figure 3 Protein structure of SF1. (a) Schematic view of the different domains of the SF1 protein. The approximate locations of previously published
variants within NR5A1 in families affected by 46,XY DSD and 46,XX POI and sporadic cases of 46,XX POI are shown below the protein structure as
resulting protein changes.11,12 The novel 3-bp deletion in exon 6 of NR5A1 (p.(Lys372del)), located within the predicted LBD, is shown above the protein
structure. (b) In silico predictions of the wild-type and (c) the p.(Lys372del) mutant SF1 proteins. The LBD is highlighted by green boxes, whereas the DBD
is highlighted by blue boxes. Comparison of the wild-type and mutant SF1 structures indicates that the deletion of Lys372 results in the truncation of helix
8 (highlighted with white boxes) of the LBD at this position. Further changes in the secondary structure of the protein include the loss of the b-pleated
sheets in both the LBD and the DBD, indicating a potential loss of the DNA-binding ability of the mutant compared with the wild-type SF1 protein.
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pCMV6-Entry-hNR5A1 vector, which contains C-terminal DDK and
c-Myc tags). We obtained two supershift signals, caused by one or two
SF1 molecules bound to the responsive element. The shift and
supershift experiments with the mutant SF1 overexpression nuclear
extracts produced one very weak shift and supershift signal (repre-
senting one SF1 molecule bound), and loss of the second signal (two
SF1 molecules bound) (see Figure 4b). This indicates that the
p.(Lys372del) mutant protein bound with a lower efficiency than
the wild-type protein to SF1-responsive elements in vitro.
To confirm these results, we performed dual-luciferase reporter
assays using the hNR0B1 (hDAX1) promoter (Figure 4c). When
co-transfecting the pGL4.10-hNR0B1 promoter vector with the wild-
type pCMV6-Entry-hNR5A1 overexpression vector, we found a 2- to
7.5-fold increase in luciferase activity compared with the reporter
construct-only transfections. The fold increase in the luciferase
activity varied between the three cell lines (15P-1, KK-1, and
Hek293) tested. When transfecting with the mutant overexpression
construct (pCMV6-Entry-hNR5A1-p.(Lys372del)), luciferase activity
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Figure 4 Functional assays on SF1 activity using the mNr0b1 and hNR0B1 SF1-responsive element and promoter. (a) Western blot of the wild-type and
mutant SF1 overexpression nuclear extracts (NE mut and NE wt, respectively) showing similar expression levels of the two proteins. Proliferating cell
nuclear antigen (PCNA) was used as loading control. (b) EMSA using the mouse Nr0b1 (mDax1) SF1-responsive element. Lane one shows the signal for the
probe, and lane two shows the signals obtained by adding the wild-type nuclear extract (wt NE). Two signals are detected owing to the composite SF1-
binding site within this element. Lane three shows the supershifts, using an anti-FLAG antibody. Lanes 4 and 5 show the results for the mutant nuclear
extract (mut NE). Both signals and supershifts, owing to SF1 binding to the probe, which were observed with the wild-type nuclear extract, are almost
completely lost when the mutant nuclear extract is added. (c) Dual-luciferase reporter assays using the hNR0B1promoter. In all three cell lines (15P-1, KK-1,
and Hek293), an increase of luciferase expression can be detected when the wild-type SF1 expression vector is added to the reporter vector (pGL4.10-
hNR0B1), whereas addition of the mutant construct results in little or no change in luciferase activity.
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remained at similar levels to the promoter construct-only transfec-
tions. These data support the results from the EMSAs, where the
mutant SF1 protein did not bind SF1-responsive elements in vitro.
Furthermore, the luciferase data showed that the mutant SF1 protein
failed to activate SF1-responsive promoters in vitro.
DISCUSSION
In this study, we identified a novel, 3-bp, in-frame deletion located in
exon 6 of NR5A1 in all seven affected family members (46,XY DSD
(unknown and gonadal dysgenesis) and 46,XX POI). As NR5A1 had
been previously described to cause both phenotypes11,12 and was
inherited in the proposed autosomal dominant manner, we focussed
on this variant as the most likely explanation for these clinical
phenotypes.
In silico prediction of the wild-type and mutant predicted SF1
protein structures suggested that the mutated lysine 372 has an
important structural role. Deletion of this single amino acid is
predicted to result in the truncation of helix 8 of the LBD and the
loss of all b-pleated sheets, in the LBD, as well as in the DBD. It is also
predicted to affect the entire tertiary protein structure, potentially
explaining the observed loss of the DNA-binding capability of the
mutant SF1 protein. The EMSAs and dual-luciferase reporter assays
with known SF1-responsive elements of downstream targets of SF1,
such as mNr0b1/hNR0B1 (mDax1/hDAX1), confirmed the in silico
prediction, showing a marked reduction in the DNA-binding and
transactivation ability of the mutant SF1 protein compared with the
wild-type SF1 protein in vitro. This indicates that the mutant SF1
protein present in the affected family members fails to bind and
activate downstream targets of SF1.
Three other variants within the LBD of NR5A1 have been described
in sporadic cases of 46,XX POI (c.691_699delCTGCAGCTG
(p.(Leu231_Leu233del)) and c.704C4T (p.(Pro235Leu))) or familial
cases of 46,XY DSD and 46,XX POI (c.877G4A (p.(Asp293Asn))).11,12
A direct comparison of the three other published variants and our
variant is difficult, as different SF1-responsive promoters and cell lines
were used; however, it appears that single amino-acid exchanges
within the LBD lead to a moderate (c.877G4A (p.(Asp293Asn))
(Cyp11a1 and Cyp19a1 promoters); c.704C4T (p.(Pro235Leu))
(Cyp17a1 promoter)) or no significant reduction (c.704C4T
(p.(Pro235Leu)) (CYP11A1 and HSD3B2 promoters) of the
activation of SF1-responsive promoters. By contrast, the effect on
the activation of SF1-responsive promoters of the single amino-acid
deletion c.1114_1115del (p.(Lys372del)) described here corresponds
to the effect seen with larger deletions c.691_699delCTGCAGCTG
(p.(Leu231_Leu233) (Cyp11a1 and Cyp19a1 promoters)) or variants
found in the DBD. This further supports the in silico prediction and
the proposed structural importance of lysine 372.
The two DSD conditions (46,XY DSD (unknown and gonadal
dysgenesis) and 46,XX POI) caused by the same variant can be
explained by the different roles of SF1 in the developing testis and
ovary. In testes, SF1 is expressed in Leydig and Sertoli cells and is
required to upregulate SRY and thus to establish the male pathway,
resulting in the bipotential gonad developing into a testis.26 SF1 has
also been shown to synergize with SRY to upregulate SOX9 and with
SOX9 to upregulate Cyp26b1.6,27 In addition, SF1 is required to
upregulate AMH expression and causing the regression of the
Mu¨llerian ducts in XY male embryos.28 In the ovary, NR5A1 is
expressed in theca and granulosa cells and its expression can be
detected in the embryonic, postnatal, prepubertal and adult ovary.29,30
SF1 has been shown to regulate key genes of ovarian steroidogenesis.
SF1 clearly acts at multiple points during gonad development,
differentiation, and in crucial steroidogenic pathways even into
adulthood. Given this, it is not surprising that the same variant in
NR5A1 can cause testis failure and 46,XY DSD (including gonadal
dysgenesis) in male family members, whereas in female relatives it
causes 46,XX POI.
We also observed that the same variant caused different external
genitalia in the three individuals with 46,XY DSD. II:8 and III:2 had
predominantly male genitalia and were raised as boys, whereas III:1
had predominantly female external genitalia at birth and was raised as
a girl. This variation is most likely explained either by incomplete
penetrance and/or by SNPs or variants in modifying genetic factors
that have yet to be identified. MPS studies on larger numbers of DSD
patients will help identify the missing genes and networks, which,
when disrupted, cause DSDs. Our findings in this family are entirely
consistent with earlier studies, which associated variants in NR5A1
with 46,XY gonadal dysgenesis and 46,XX POI in families. High
variability in the phenotype of the external genitalia in familial cases
of 46,XY DSD has also been reported.31
This study has shown the particular utility of using low-coverage
MPS and linkage analysis to identify rapidly the causative variant. In
an effort to reduce costs, many groups select a few individuals from
large pedigrees for MPS at high coverage. As an alternative, the
approach used here involved sequencing more individuals to ensure
sufficient power for linkage analysis, combined with cheaper low-
coverage MPS to identify the disease-causing genes at a similar cost.
The identification of the molecular cause and the mode of inheritance
of 46,XY DSD (including cases of 46,XY gonadal dysgenesis) and
46,XX POI in families such as this allows for the provision of genetic
counselling to female family members under or at a reproductive age,
as they may carry a dominant variant, but have not presented with
secondary amenorrhoea. The two girls (III:3 and III:4) in this family
are in this situation. Although their mother (II:4) carried the variant
in NR5A1 and was affected by 46,XX POI, both her daughters tested
negative for the variant and were not at risk for POI.
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